AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20129511 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 4 mg/kg/day for 7 days followed by 6 mg/kg/day for 14 days
Number of subjects: 9
Study 20129511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17509511 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.02% mitomycin C (MMC) applied for 15 seconds during PRK
Number of subjects: 15
Study 17509511 — intervention group
Group type: COMPARATOR
Intervention: Epi-LASIK (control group)
Number of subjects: 15
Study 16284692 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic parenteral nutrition (PN)
Number of subjects: 44
Study 16284692 — intervention group
Group type: EXPERIMENTAL
Intervention: PN with 0.5 g glutamine/kg as L‐Ala‐L‐Gln
Number of subjects: 44
Study 16284692 — intervention group
Group type: COMPARATOR
Intervention: Standard PN
Number of subjects: 44
Study 16284692 — intervention group
Group type: COMPARATOR
Intervention: PN given ad hoc
Number of subjects: 44
Study 11907712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 108
Study 10542923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterosuperior quadrant insertion of Shah grommet ventilation tube
Number of subjects: 54
Study 10542923 — intervention group
Group type: COMPARATOR
Intervention: Anteroinferior quadrant insertion of Shah grommet ventilation tube
Number of subjects: 54
Study 7778387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (daily dose 1-2 grams)
Number of subjects: 226
Study 7778387 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 226
Study 2316281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 0.03-3.0 micrograms antigen per dose
Number of subjects: 56
Study 2316281 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 37045 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate 2 mg
Number of subjects: 0
Study 37045 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate 4 mg
Number of subjects: 0
Study 37045 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate 8 mg
Number of subjects: 0
Study 37045 — intervention group
Group type: COMPARATOR
Intervention: Dexchlorpheniramine 4 mg
Number of subjects: 0
Study 37045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31190327 — intervention group
Group type: EXPERIMENTAL
Intervention: ENR-IV (10 mg/kg, IV)
Number of subjects: 24
Study 31190327 — intervention group
Group type: EXPERIMENTAL
Intervention: ENR-IM (10 mg/kg, IM)
Number of subjects: 24
Study 31190327 — intervention group
Group type: EXPERIMENTAL
Intervention: DNX-IV (8 mg/kg, IV)
Number of subjects: 24
Study 31190327 — intervention group
Group type: EXPERIMENTAL
Intervention: DNX-IM (8 mg/kg, IM)
Number of subjects: 24
Study 31190327 — intervention group
Group type: EXPERIMENTAL
Intervention: ENR and DNX (IV and IM)
Number of subjects: 24
Study 28873160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific reminders group (496 GPs, 10,476 patients)
Number of subjects: 33044
Study 28873160 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic reminders group (495 GPs, 10,606 patients)
Number of subjects: 33044
Study 28873160 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (455 GPs, 10,147 patients)
Number of subjects: 33044
Study 26506165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic stimulation
Number of subjects: 32
Study 26506165 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stimulation
Number of subjects: 32
Study 26506165 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 32
Study 24148291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methimazole ointment applied to the skin around the thyroid and an oral placebo
Number of subjects: 144
Study 24148291 — intervention group
Group type: COMPARATOR
Intervention: Methimazole tablets and placebo ointment
Number of subjects: 144
Study 24148291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methimazole ointment
Number of subjects: 144
Study 24148291 — intervention group
Group type: COMPARATOR
Intervention: Methimazole tablets
Number of subjects: 144
Study 21798557 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of 1‐month depot leuprolide acetate (DL)
Number of subjects: 54
Study 21798557 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg of 3‐month depot leuprolide acetate (DL)
Number of subjects: 54
Study 21798557 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5 mg of 3‐month depot leuprolide acetate (DL)
Number of subjects: 54
Study 19689546 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort O2 (ONSI‐56) lenses
Number of subjects: 30
Study 19689546 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston XO lenses
Number of subjects: 30
Study 19689546 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no specific control group mentioned)
Number of subjects: 30
Study 16867922 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder with concurrent substance use disorder (SUD)
Number of subjects: 2541
Study 16867922 — intervention group
Group type: COMPARATOR
Intervention: Major depressive disorder without concurrent substance use disorder (SUD)
Number of subjects: 2541
Study 12552189 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-fentanyl
Number of subjects: 117
Study 12552189 — intervention group
Group type: COMPARATOR
Intervention: isoflurane-fentanyl
Number of subjects: 117
Study 10506597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with doxorubicin 75 mg/m(2) every 2 weeks for three cycles followed by docetaxel 100 mg/m(2) every 2 weeks for three cycles
Number of subjects: 40
Study 10506597 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with doxorubicin 56 mg/m(2) plus docetaxel 75 mg/m(2) every 3 weeks for four cycles
Number of subjects: 40
Study 8891961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (COTEE)
Number of subjects: 13
Study 8891961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fick method (COFICK)
Number of subjects: 13
Study 8891961 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution (COTD)
Number of subjects: 13
Study 8891961 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta COTEE
Number of subjects: 13
Study 8891961 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta COFICK
Number of subjects: 13
Study 1671951 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol liquid 10-15 mg/kg every 4 hours as needed for fever
Number of subjects: 225
Study 1671951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 1671951 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 225
Study 6383513 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole
Number of subjects: 0
Study 6383513 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30297537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic infarction type 2
Number of subjects: 478
Study 30297537 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal hematoma type 2
Number of subjects: 478
Study 30297537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic infarction type 1
Number of subjects: 478
Study 30297537 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal hematoma type 1
Number of subjects: 478
Study 28985094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management for first-time dislocation without osteochondral fragment or loose body
Number of subjects: 0
Study 28985094 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for first-time dislocation with operative osteochondral fracture requiring excision or repair
Number of subjects: 0
Study 28985094 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent instability, favoring medial reconstruction
Number of subjects: 0
Study 28985094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony procedures to correct underlying bony deformities
Number of subjects: 0
Study 28985094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral release for patellar instability
Number of subjects: 0
Study 26965534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 180
Study 26965534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid
Number of subjects: 180
Study 26965534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 24220913 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP concentrations ≥ 10.0 mg/L
Number of subjects: 2919
Study 23082602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level oral health intervention (home visits by lay health workers, enhancing oral health education and services at health centers, community mobilization)
Number of subjects: 0
Study 23082602 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (caregivers receiving the intervention)
Number of subjects: 0
Study 23082602 — intervention group
Group type: COMPARATOR
Intervention: Control group (caregivers not receiving the intervention)
Number of subjects: 0
Study 21146663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower height-z patients (n=124, 23%)
Number of subjects: 544
Study 21146663 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI-z patients (n=45, 8%)
Number of subjects: 544
Study 21146663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI-z patients (n=53, 10%)
Number of subjects: 544
Study 17986898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (SHORT: 30 min, 65% VO2max)
Number of subjects: 18
Study 17986898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (LONG: 60 min, 65% VO2max)
Number of subjects: 18
Study 17986898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (INTENSE: 6 x 3 min, 90% VO2max)
Number of subjects: 18
Study 17986898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (any intensity)
Number of subjects: 18
Study 15855573 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer (GW2B) plus standard glucose monitoring
Number of subjects: 200
Study 15855573 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose monitoring (usual care)
Number of subjects: 200
Study 11990270 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 10 mg
Number of subjects: 40
Study 11990270 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 40
Study 10543733 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of body weight daily
Number of subjects: 30
Study 10543733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg daily
Number of subjects: 30
Study 10543733 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg weekly
Number of subjects: 30
Study 10543733 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 8559630 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (fourth dose)
Number of subjects: 182
Study 8559630 — intervention group
Group type: COMPARATOR
Intervention: Acellular pertussis vaccine (booster)
Number of subjects: 182
Study 2378546 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d of haloperidol
Number of subjects: 80
Study 2378546 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of haloperidol
Number of subjects: 80
Study 2378546 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d of haloperidol
Number of subjects: 80
Study 356962 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 38
Study 356962 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus Bacillus Calmette‐Guérin
Number of subjects: 38
Study 31957952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional microneedle radiofrequency (FMR)
Number of subjects: 10
Study 31957952 — intervention group
Group type: COMPARATOR
Intervention: Fractional radiofrequency (FR)
Number of subjects: 10
Study 31657804 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 improvisational music therapy sessions on a weekly basis (Group 1)
Number of subjects: 24
Study 31657804 — intervention group
Group type: COMPARATOR
Intervention: 7 improvisational music therapy sessions alternated with 7 listening music therapy sessions on a weekly basis (Group 2)
Number of subjects: 24
Study 28382893 — intervention group
Group type: EXPERIMENTAL
Intervention: fruit
Number of subjects: 165
Study 28382893 — intervention group
Group type: EXPERIMENTAL
Intervention: fruit+reward
Number of subjects: 165
Study 28382893 — intervention group
Group type: COMPARATOR
Intervention: unhealthy snacks
Number of subjects: 165
Study 27116860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam protection
Number of subjects: 36
Study 27116860 — intervention group
Group type: COMPARATOR
Intervention: Cotton rolls isolation (Control)
Number of subjects: 36
Study 24293132 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML 40/10 mg
Number of subjects: 600
Study 24293132 — intervention group
Group type: COMPARATOR
Intervention: PER/AML 8/10 mg
Number of subjects: 600
Study 20585834 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin therapy
Number of subjects: 100
Study 20585834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean warfarin requirements ≤ 3 mg/day
Number of subjects: 100
Study 20585834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean warfarin requirements > 3 mg/day
Number of subjects: 100
Study 19217632 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24
Study 19217632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17902000 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy group (TG) received one-session cognitive behavior therapy (CBT).
Number of subjects: 26
Study 17902000 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (WG) did not receive therapy during the study period.
Number of subjects: 26
Study 15334793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 300
Study 15334793 — intervention group
Group type: COMPARATOR
Intervention: Chinolones
Number of subjects: 300
Study 11727285 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets prepared with Helinx technology
Number of subjects: 0
Study 11727285 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet transfusions (implied control)
Number of subjects: 0
Study 9594322 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐SK
Number of subjects: 173
Study 9594322 — intervention group
Group type: COMPARATOR
Intervention: SK
Number of subjects: 173
Study 7936246 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 7936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (side of stenosis)
Number of subjects: 0
Study 7936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (normal side)
Number of subjects: 0
Study 7936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (one month after carotid endarterectomy, side of stenosis)
Number of subjects: 0
Study 7936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (one month after carotid endarterectomy, normal side)
Number of subjects: 0
Study 2595039 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (median dose 1.1 mg, range 0.5-2.6 mg)
Number of subjects: 76
Study 2595039 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum (median dose 10 mg, range 5-15 mg) and Diazepam (median dose 8 mg, range 0-20 mg)
Number of subjects: 76
Study 2595039 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 76
Study 1106038 — intervention group
Group type: EXPERIMENTAL
Intervention: Safapryn (3.6 g aspirin + 3.0 g paracetamol daily)
Number of subjects: 122
Study 1106038 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (3000 mg)
Number of subjects: 122
Study 1106038 — intervention group
Group type: COMPARATOR
Intervention: 50 mg phenylbutazone daily
Number of subjects: 122
Study 31625704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 132
Study 31625704 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (ACE inhibitors or ARBs)
Number of subjects: 132
Study 28760590 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal ointment
Number of subjects: 80
Study 28760590 — intervention group
Group type: COMPARATOR
Intervention: Honey vaginal ointment
Number of subjects: 80
Study 25674350 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illness (IMNCI) strategy
Number of subjects: 18
Study 25674350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 23260167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management consultations
Number of subjects: 3851
Study 23260167 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy package (up to six sessions)
Number of subjects: 3851
Study 23260167 — intervention group
Group type: COMPARATOR
Intervention: Usual care consultations
Number of subjects: 3851
Study 23260167 — intervention group
Group type: COMPARATOR
Intervention: Single physiotherapy advice session
Number of subjects: 3851
Study 21663857 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 38 mg/m²
Number of subjects: 130
Study 21663857 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m²
Number of subjects: 130
Study 19636254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 28
Study 19636254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22067557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric AcrySof SN60WF IOL
Number of subjects: 47
Study 22067557 — intervention group
Group type: COMPARATOR
Intervention: Spherical AcrySof SN60AT IOL
Number of subjects: 47
Study 15830733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (1 mg/kg every 30 min) with oral alcohol (1 g/kg following the initial cocaine dose and a second drink at +60 min)
Number of subjects: 17
Study 15830733 — intervention group
Group type: COMPARATOR
Intervention: Cocaine and alcohol placebo
Number of subjects: 17
Study 15830733 — intervention group
Group type: COMPARATOR
Intervention: Cocaine placebo and alcohol
Number of subjects: 17
Study 12855610 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of zoledronic acid (Zol)
Number of subjects: 0
Study 12855610 — intervention group
Group type: COMPARATOR
Intervention: 8 mg of zoledronic acid (Zol)
Number of subjects: 0
Study 12855610 — intervention group
Group type: COMPARATOR
Intervention: zoledronic acid (Zol)
Number of subjects: 0
Study 9856709 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (3 microg/ml) alone
Number of subjects: 100
Study 9856709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with 0.01% bupivacaine
Number of subjects: 100
Study 9856709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with 0.5 microg/ml epinephrine
Number of subjects: 100
Study 9856709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with both 0.01% bupivacaine and 0.5 microg/ml epinephrine
Number of subjects: 100
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat length analysis
Number of subjects: 71
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal transmission of CAG repeats
Number of subjects: 71
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal transmission of CAG repeats
Number of subjects: 71
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: Father-child differences in repeat length
Number of subjects: 71
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat length analysis as a diagnostic test
Number of subjects: 71
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansion of CAG repeats
Number of subjects: 71
Study 7824105 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of transmitting parent's sex
Number of subjects: 71
Study 2215707 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic blood pressure meter
Number of subjects: 76
Study 2215707 — intervention group
Group type: COMPARATOR
Intervention: Mercury manometer
Number of subjects: 76
Study 382154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% domperidone drops (0.3 mg/kg t.d.s. before meals)
Number of subjects: 47
Study 382154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metoclopramide drops (0.3 mg/kg t.d.s. before meals)
Number of subjects: 47
Study 382154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11383934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) treatment with imaging exclusion criteria
Number of subjects: 30
Study 11383934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) treatment
Number of subjects: 30
Study 31508533 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Mg) during even-numbered chemotherapy courses (arm AB)
Number of subjects: 40
Study 31508533 — intervention group
Group type: COMPARATOR
Intervention: No magnesium supplementation during odd-numbered chemotherapy courses (arm BA)
Number of subjects: 40
Study 31508533 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Mg)
Number of subjects: 40
Study 31508533 — intervention group
Group type: COMPARATOR
Intervention: No magnesium supplementation
Number of subjects: 40
Study 29370555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130
Study 29370555 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 130
Study 27443660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmathen quetiapine 400 mg prolonged-release formulation
Number of subjects: 48
Study 27443660 — intervention group
Group type: COMPARATOR
Intervention: AstraZeneca Seroquel Prolong® 400 mg prolonged-release formulation
Number of subjects: 48
Study 25374047 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sided message describing the advantages of HIV testing
Number of subjects: 1919
Study 25374047 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided message acknowledging a superficial objection (20 minute wait for results)
Number of subjects: 1919